Novartis Aktie
WKN: 904278 / ISIN: CH0012005267
17.10.2025 20:02:58
|
Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial
This article Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial originally appeared on Benzinga.com.Weiter zum vollständigen Artikel bei Benzinga

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novartis AGmehr Nachrichten
17.10.25 |
Press Release: Novartis Kisqali(R) 5-year NATALEE -2- (Dow Jones) | |
17.10.25 |
Press Release: Novartis Kisqali(R) 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population (Dow Jones) | |
17.10.25 |
Press Release: Novartis Scemblix(R) receives -2- (Dow Jones) | |
17.10.25 |
Press Release: Novartis Scemblix(R) receives positive CHMP opinion for the treatment of adults with newly diagnosed CML (Dow Jones) | |
16.10.25 |
Press Release: Novartis Fabhalta(R) (iptacopan) -2- (Dow Jones) | |
16.10.25 |
Press Release: Novartis Fabhalta(R) (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN) (Dow Jones) | |
15.10.25 |
Zuversicht in Zürich: So steht der SLI am Nachmittag (finanzen.at) | |
15.10.25 |
Starker Wochentag in Zürich: SMI am Mittwochnachmittag freundlich (finanzen.at) |
Analysen zu Novartis AGmehr Analysen
13.10.25 | Novartis Neutral | UBS AG | |
10.10.25 | Novartis Neutral | UBS AG | |
06.10.25 | Novartis Buy | Deutsche Bank AG | |
24.09.25 | Novartis Neutral | UBS AG | |
22.09.25 | Novartis Neutral | UBS AG |
Aktien in diesem Artikel
Novartis AG 2. Linie | 103,88 | -0,31% |
|
Novartis AG ADR Cert. Deposito Arg. Repr. 0.5 ADRs | 48 620,00 | 2,79% |
|
Novartis AG (Spons. ADRS) | 112,50 | 1,35% |
|
Novartis AG | 112,65 | 0,85% |
|
Trial Holdings Inc. Registered Shs | 2 181,00 | -1,58% |
|